Related Experiment Videos
18-FDG imaging in breast cancer
1Department of Molecular and Medical Pharmacology, UCLA School of Medicine, USA.
Seminars in Nuclear Medicine
|February 17, 1999
Summary
18-fluorodeoxyglucose (FDG) positron emission tomography (PET) shows promise for breast cancer management. This review covers its use in detecting lesions, staging lymph nodes, finding residual/metastatic disease, and monitoring chemotherapy response.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiology
Background:
- Breast cancer is a significant health concern with limited published data on 18-fluorodeoxyglucose (FDG) applications.
- Current diagnostic and monitoring strategies for breast cancer can be improved with advanced imaging techniques.
Purpose of the Study:
- To summarize existing research on 18-fluorodeoxyglucose (FDG) in breast cancer evaluation.
- To present expert opinions from oncologists on FDG's clinical utility.
- To discuss the future implications of positron imaging in breast cancer management.
Main Methods:
- Literature review of studies applying 18-fluorodeoxyglucose (FDG) in breast cancer.
- Compilation of clinical oncologist perspectives from academic and community settings.
- Analysis of potential applications of positron imaging technology.
Main Results:
- 18-fluorodeoxyglucose (FDG) has potential applications in four key areas of breast cancer care.
- These areas include primary lesion detection, axillary lymph node staging, residual/metastatic disease identification, and chemotherapy response monitoring.
- Expert opinions suggest a growing interest in FDG's role, though widespread adoption varies.
Conclusions:
- 18-fluorodeoxyglucose (FDG) positron emission tomography (PET) offers a versatile tool for breast cancer management.
- Further research and clinical integration are needed to fully realize its potential.
- Positron imaging technology is poised to play an increasingly important role in personalized breast cancer treatment.